Pfizer CEO’s revelation about the COVID vaccine

by

Vaccines

Getty Images

Pfizer’s CEO assures us that a third vaccine against the coronavirus cannot be ruled out.

Pfizer’s CEO, Albert Bourla, said it is likely that those who received the two doses of the COVID-19 vaccine will require a third dose to bolster the drug’s effectiveness.

As reported by CNN, Bourla made those comments during a CBS Health companies forum. In dialogue with his colleagues, the Pfizer CEO said the evidence shows that the coronavirus vaccine loses its effectiveness over the months. Therefore, a third dose may be required.

“A likely scenario is that a third dose will probably be needed somewhere between six and 12 months and then there will be a revaccination. But all this needs to be confirmed, ‘Bourla said.

“If you ask me, I think based on this data, there will be a need for revaccination,” added Pfizer’s CEO.

It should be noted that Bourla’s words are not official. It is a prediction based on the data available to the leader of the pharmaceutical company.

Pfizer has already announced that its vaccine would guarantee 95% efficacy against severe hospitalizations for up to six months after the second dose is administered. 12 thousand vaccinated patients took part in this study. The company’s scientific team stressed the partial and probable nature of the results.

The United States is evaluating boosting vaccine doses

In line with concerns from Pfizer and the rest of the drug companies, the US government is evaluating the possibility of applying a third dose of the coronavirus vaccine.

This was confirmed by David Kessler, scientific director of the Joe Biden administration’s response to COVID-19.

Kessler said new variants of the coronavirus could “challenge” the effectiveness of vaccines.

“It seems strong, but there is some deterioration and certainly the variants are challenging… they make these vaccines work more. So I think for planning purposes, just for planning purposes, I think we should expect to move forward, ”he told the House Select Subcommittee on Coronavirus Response.

The US will invest millions to track down new variants of COVID-19

Joe Biden’s government will invest $ 1.7 billion to detect new variants of the coronavirus in the United States.

The amount comes from the US bailout through the Centers for Disease Control and Prevention (CDC). It will target the different states to detect the circulation of new variants of the disease at an early stage.

It is an ambitious plan consisting of tracing the genomic sequence of the viruses registered in the different infected persons. The United States is already engaged in these investigations. Biden’s government has allocated $ 200 million, which is equivalent to 29,000 genomic sequences per week.

The new financing would mean a greater working capacity. It would also allow states to have their own resources to conduct their studies without relying on the CDC’s central headquarters.

READ MORE: Joe Biden Begins To Roll Back Abortion Restrictions: What Action Has He Taken?

Follow Now Same on Instagram

Source